[
  {
    "ts": null,
    "headline": "Elevance Health Q3 Earnings Beat Estimates on Strong MA Membership",
    "summary": "ELV beats EPS estimates by 21% in Q3 as strong Medicare Advantage membership gains and Carelon revenue growth offset Medicaid losses.",
    "url": "https://finnhub.io/api/news?id=252cd1e04a1972c69acb518e71a4d027ea37c056d99d05b269fd0cadfddb494c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761069900,
      "headline": "Elevance Health Q3 Earnings Beat Estimates on Strong MA Membership",
      "id": 137188482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "ELV beats EPS estimates by 21% in Q3 as strong Medicare Advantage membership gains and Carelon revenue growth offset Medicaid losses.",
      "url": "https://finnhub.io/api/news?id=252cd1e04a1972c69acb518e71a4d027ea37c056d99d05b269fd0cadfddb494c"
    }
  },
  {
    "ts": null,
    "headline": "Zimmer Biomet Holdings Inc. (ZBH): 2025 Product Pipeline Analysis by Equipment Type, Indication, Development Stage, and Trial Status",
    "summary": "Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The \"Zimmer Biomet Holdings Inc (ZBH) - Product Pipeline Analysis, 2025 Update\" has been added to ResearchAndMarkets.com's offering. This comprehensive report serves as an essential source of data, analysis, and actionable intelligence regarding Zimmer Biomet's extensive portfolio of pipeline products. Detailed insights into the company's operations, major products, and brands are accompanied by analyses designed to enhance decision-making capabilities a",
    "url": "https://finnhub.io/api/news?id=eb0527f26a162a35ab2d5913ab0396bdd67469d23520ea92a19389ebbc8c1ccc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761059460,
      "headline": "Zimmer Biomet Holdings Inc. (ZBH): 2025 Product Pipeline Analysis by Equipment Type, Indication, Development Stage, and Trial Status",
      "id": 137181038,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The \"Zimmer Biomet Holdings Inc (ZBH) - Product Pipeline Analysis, 2025 Update\" has been added to ResearchAndMarkets.com's offering. This comprehensive report serves as an essential source of data, analysis, and actionable intelligence regarding Zimmer Biomet's extensive portfolio of pipeline products. Detailed insights into the company's operations, major products, and brands are accompanied by analyses designed to enhance decision-making capabilities a",
      "url": "https://finnhub.io/api/news?id=eb0527f26a162a35ab2d5913ab0396bdd67469d23520ea92a19389ebbc8c1ccc"
    }
  },
  {
    "ts": null,
    "headline": "Will ISRG's dV5 Lend Momentum to Top Line During Q3 Earnings?",
    "summary": "Intuitive Surgical's new da Vinci 5 is driving strong hospital upgrades and premium pricing, setting up ISRG for potential top-line momentum in Q3.",
    "url": "https://finnhub.io/api/news?id=3dae0a15ed3a551fc3e182574d322c776d8018cc913571900f987159c726b4cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761051480,
      "headline": "Will ISRG's dV5 Lend Momentum to Top Line During Q3 Earnings?",
      "id": 137178220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Intuitive Surgical's new da Vinci 5 is driving strong hospital upgrades and premium pricing, setting up ISRG for potential top-line momentum in Q3.",
      "url": "https://finnhub.io/api/news?id=3dae0a15ed3a551fc3e182574d322c776d8018cc913571900f987159c726b4cf"
    }
  },
  {
    "ts": null,
    "headline": "Zimmer Biomet to Report Q3 Earnings: Here's What to Expect",
    "summary": "ZBH's Q3 results on Nov. 5 may show solid gains, driven by hip, knee, and S.E.T. segment growth and recent product approvals.",
    "url": "https://finnhub.io/api/news?id=c7316eb7e0e80687ccf5c4e2e32de7b2402f934858d4152db700728e9575d96e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761051360,
      "headline": "Zimmer Biomet to Report Q3 Earnings: Here's What to Expect",
      "id": 137178643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "ZBH's Q3 results on Nov. 5 may show solid gains, driven by hip, knee, and S.E.T. segment growth and recent product approvals.",
      "url": "https://finnhub.io/api/news?id=c7316eb7e0e80687ccf5c4e2e32de7b2402f934858d4152db700728e9575d96e"
    }
  },
  {
    "ts": null,
    "headline": "Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting",
    "summary": "Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting bold innovations across its broad robotics and musculoskeletal portfolio at the 2025 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).",
    "url": "https://finnhub.io/api/news?id=249e7187c360f12e1bedef44dd9d05c9709a167427576ffcceeab7a84bcd7b6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761046200,
      "headline": "Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting",
      "id": 137178644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting bold innovations across its broad robotics and musculoskeletal portfolio at the 2025 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).",
      "url": "https://finnhub.io/api/news?id=249e7187c360f12e1bedef44dd9d05c9709a167427576ffcceeab7a84bcd7b6d"
    }
  },
  {
    "ts": null,
    "headline": "Zimmer Biomet (ZBH): Evaluating Valuation After Recent Share Price Momentum",
    "summary": "Zimmer Biomet Holdings (ZBH) shares have made steady progress in recent weeks, with the stock climbing 8% over the past month. Investors seem to be weighing the company's fundamentals as it navigates a shifting healthcare landscape. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet’s recent 8% weekly share price rally follows a period of steady long-term performance, though its 1-year total shareholder return remains slightly negative at -1.4%. This suggests that investors are...",
    "url": "https://finnhub.io/api/news?id=3d3cc859c059b22ad1767050cc257444893b6056fbfea6bddbce636f613f0667",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761008962,
      "headline": "Zimmer Biomet (ZBH): Evaluating Valuation After Recent Share Price Momentum",
      "id": 137174895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Zimmer Biomet Holdings (ZBH) shares have made steady progress in recent weeks, with the stock climbing 8% over the past month. Investors seem to be weighing the company's fundamentals as it navigates a shifting healthcare landscape. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet’s recent 8% weekly share price rally follows a period of steady long-term performance, though its 1-year total shareholder return remains slightly negative at -1.4%. This suggests that investors are...",
      "url": "https://finnhub.io/api/news?id=3d3cc859c059b22ad1767050cc257444893b6056fbfea6bddbce636f613f0667"
    }
  }
]